32321403|t|Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders.
32321403|a|Dementia is an important issue in western societies, and in the following years, this problem will also rise in the developing regions, such as Africa and Asia. The most common types of dementia in adults are Alzheimer's Disease (AD), Dementia with Lewy Bodies (DLB), Frontotemporal Dementia (FTD) and Vascular Dementia (VaD), of which, AD accounts for more than half of the cases. The most prominent symptom of AD is cognitive impairment, currently treated with four drugs: Donepezil, rivastigmine, and galantamine, enhancing cholinergic transmission; as well as memantine, protecting neurons against glutamate excitotoxicity. Despite ongoing efforts, no new drugs in the treatment of AD have been registered for the last ten years, thus multiple studies have been conducted on genetic factors affecting the efficacy of antidementia pharmacotherapy. The researchers investigate the effects of variants in multiple genes, such as ABCB1, ACE, CHAT, CHRNA7, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP3A7, NR1I2, NR1I3, POR, PPAR, RXR, SLC22A1/2/5, SLC47A1, UGT1A6, UGT1A9 and UGT2B7, associated with numerous pathways: the development of pathological proteins, formation and metabolism of acetylcholine, transport, metabolism and excretion of antidementia drugs and transcription factors regulating the expression of genes responsible for metabolism and transport of drugs. The most promising results have been demonstrated for APOE E4, dementia risk variant, BCHE-K, reduced butyrylcholinesterase activity variant, and CYP2D6 UM, ultrarapid hepatic metabolism. Further studies investigate the possibilities of the development of emerging drugs or genetic editing by CRISPR/Cas9 for causative treatment. In conclusion, the pharmacogenetic studies on dementia diseases may improve the efficacy of pharmacotherapy in some patients with beneficial genetic variants, at the same time, identifying the carriers of unfavorable alleles, the potential group of novel approaches to the treatment and prevention of dementia.
32321403	70	94	Neurocognitive Disorders	Disease	MESH:D019965
32321403	96	104	Dementia	Disease	MESH:D003704
32321403	282	290	dementia	Disease	MESH:D003704
32321403	305	324	Alzheimer's Disease	Disease	MESH:D000544
32321403	326	328	AD	Disease	MESH:D000544
32321403	331	356	Dementia with Lewy Bodies	Disease	MESH:D020961
32321403	358	361	DLB	Disease	MESH:D020961
32321403	364	387	Frontotemporal Dementia	Disease	MESH:D057180
32321403	389	392	FTD	Disease	MESH:D057180
32321403	398	415	Vascular Dementia	Disease	MESH:D015140
32321403	417	420	VaD	Disease	MESH:D015140
32321403	433	435	AD	Disease	MESH:D000544
32321403	508	510	AD	Disease	MESH:D000544
32321403	514	534	cognitive impairment	Disease	MESH:D003072
32321403	571	580	Donepezil	Chemical	MESH:D000077265
32321403	582	594	rivastigmine	Chemical	MESH:D000068836
32321403	600	611	galantamine	Chemical	MESH:D005702
32321403	660	669	memantine	Chemical	MESH:D008559
32321403	698	707	glutamate	Chemical	MESH:D018698
32321403	708	722	excitotoxicity	Disease	
32321403	782	784	AD	Disease	MESH:D000544
32321403	1026	1031	ABCB1	Gene	5243
32321403	1033	1036	ACE	Gene	163
32321403	1038	1042	CHAT	Gene	1103
32321403	1044	1050	CHRNA7	Gene	1139
32321403	1052	1058	CYP2C9	Gene	1559
32321403	1060	1067	CYP2C19	Gene	1557
32321403	1069	1075	CYP2D6	Gene	1565
32321403	1077	1083	CYP3A4	Gene	1576
32321403	1085	1091	CYP3A5	Gene	1577
32321403	1093	1099	CYP3A7	Gene	1551
32321403	1101	1106	NR1I2	Gene	8856
32321403	1108	1113	NR1I3	Gene	9970
32321403	1115	1118	POR	Gene	5447
32321403	1120	1124	PPAR	Gene	5465
32321403	1126	1129	RXR	Gene	6256
32321403	1131	1142	SLC22A1/2/5	Gene	6580
32321403	1144	1151	SLC47A1	Gene	55244
32321403	1153	1159	UGT1A6	Gene	54578
32321403	1161	1167	UGT1A9	Gene	54600
32321403	1172	1178	UGT2B7	Gene	7364
32321403	1285	1298	acetylcholine	Chemical	MESH:D000109
32321403	1533	1541	dementia	Disease	MESH:D003704
32321403	1572	1593	butyrylcholinesterase	Gene	590
32321403	1616	1622	CYP2D6	Gene	1565
32321403	1846	1863	dementia diseases	Disease	MESH:D003704
32321403	1916	1924	patients	Species	9606
32321403	2101	2109	dementia	Disease	MESH:D003704
32321403	Negative_Correlation	MESH:D000077265	MESH:D003072
32321403	Negative_Correlation	MESH:D005702	MESH:D000544
32321403	Negative_Correlation	MESH:D008559	MESH:D003072
32321403	Negative_Correlation	MESH:D000068836	MESH:D003072
32321403	Association	MESH:D003704	1565
32321403	Negative_Correlation	MESH:D000077265	MESH:D000544
32321403	Negative_Correlation	MESH:D008559	MESH:D018698
32321403	Negative_Correlation	MESH:D005702	MESH:D003072
32321403	Negative_Correlation	MESH:D000068836	MESH:D000544
32321403	Negative_Correlation	MESH:D000077265	MESH:D018698
32321403	Negative_Correlation	MESH:D008559	MESH:D000544

